Jco Precision Oncology

Personalized Prophylactic Antiemetic Regimens for Control of Chemotherapy-Induced Nausea and Vomiting by Pharmacogenetic Analysis of Three Receptor Genes: HTR3A, HTR3B, TACR1.

Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor-Resistant Breast Cancer From the GEICAM/2013-02 PEARL Trial.

Mucin 16-Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes.

针对儿童肉瘤的 Mucin 16 靶向治疗：Ubamatamab 在上皮样肉瘤中的疗效病例证据及其对其他肉瘤亚型的意义

Cellular Mass Response to Therapy Correlates With Clinical Response for a Range of Malignancies.

Genomic Profiling of Rare Undifferentiated Sarcomatoid Subtypes of Pancreatic Carcinomas: In Search of Therapeutic Targets.

Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy.

采用迭代式腹腔热灌注化疗治疗高级别阑尾癌的突变特征和肿瘤微环境改变

Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.

黑素皮质素-1受体表达作为黑色素瘤进展的标志物

Discovery of Gene Fusions in Driver-Negative Cancer Samples From the National Cancer Institute-Molecular Analysis for Therapy Choice Screening Cohort.

在国家癌症研究所分子分析治疗选择筛查队列中，发现驱动基因阴性癌症样本中的基因融合

Personalized Therapy Selection by Integration of Molecular Cancer Classification by the 92-Gene Assay and Tumor Profiling in Patients With Cancer of Unknown Primary

通过整合 92 基因检测的分子癌症分类和肿瘤分析，为原发灶不明的癌症患者提供个性化治疗选择

Modeling Extraordinary Response Through Targeting Secondary Alterations in Fusion-Associated Sarcoma

通过针对融合相关肉瘤中的继发性改变来建模非凡反应